Catalent Completes Chinese Softgel Acquisition

- Last updated on GMT

Related tags: China, Management

Catalent Completes Chinese Softgel Acquisition
Catalent has completed the purchase of a Chinese softgel firm following regulatory approval.

The acquisition of Zhejiang Jiang Yuan Tang Biotechnology was agreed back in March with Catalent Pharma Solutions telling in-Pharmatechnologist.com​ the deal would build upon its existing softgel network in Asia Pacific and complement existing facilities in Japan and Australia.

Now with regulatory requirements met, the firm holds the majority share of Zhejiang Jiang Yuan Tang, based in Haining, and employer of 120.

Speaking in March, Catalent spokesperson Chris Halling told us: “Growing our capabilities in China and Asia more broadly is a key goal for Catalent and has commanded substantial focus from Catalent senior management over the last year and will continue to in the future.”

In April Catalent named Weiyan “Jackson” Zhu​ as Country General Manager for China.

The firm is also targeting the Asian market with a 31,000 sq ft clinical trials facility under construction in Shanghai.

Related news

Show more

Related product

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers